Skip to content

Advertisement

Journal for ImmunoTherapy of Cancer

Clinical/Translational Cancer Immunotherapy

Section edited by Dr. James L. Gulley

First-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, combination therapies, and cell therapies.

Previous Page Page 1 of 4 Next Page
  1. Content type: Research article

    An elevated Neutrophil-to-lymphocyte ratio (NLR) is associated with worse outcomes in several malignancies. However, its role with contemporary immune checkpoint blockade (ICB) is unknown. We investigated the ...

    Authors: Aly-Khan A. Lalani, Wanling Xie, Dylan J. Martini, John A. Steinharter, Craig K. Norton, Katherine M. Krajewski, Audrey Duquette, Dominick Bossé, Joaquim Bellmunt, Eliezer M. Van Allen, Bradley A. McGregor, Chad J. Creighton, Lauren C. Harshman and Toni K. Choueiri

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:5

    Published on:

  2. Content type: Short report

    Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase ...

    Authors: Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Céleste Lebbé, Michele Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Anja von Heydebreck, Meliessa Hennessy and Paul Nghiem

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:7

    Published on:

  3. Content type: Research article

    Tumor-derived autophagosome vaccines (DRibbles) have the potential to broaden immune response to poorly immunogenic tumors.

    Authors: Rachel E. Sanborn, Helen J. Ross, Sandra Aung, Anupama Acheson, Tarsem Moudgil, Sachin Puri, Traci Hilton, Brenda Fisher, Todd Coffey, Christopher Paustian, Michael Neuberger, Edwin Walker, Hong-Ming Hu, Walter J. Urba and Bernard A. Fox

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:103

    Published on:

  4. Content type: Research article

    We have previously shown that radiotherapy (RT) augments natural killer (NK) functions in pre-clinical models of human and mouse cancers, including sarcomas. Since dogs are an excellent outbred model for immun...

    Authors: Robert J. Canter, Steven K. Grossenbacher, Jennifer A. Foltz, Ian R. Sturgill, Jiwon S. Park, Jesus I. Luna, Michael S. Kent, William T. N. Culp, Mingyi Chen, Jaime F. Modiano, Arta M. Monjazeb, Dean A. Lee and William J. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:98

    Published on:

  5. Content type: Research article

    Immune related adverse events (irAEs) are associated with immunotherapy for cancer and while results suggest improvement in tumor control and overall survival in those experiencing irAEs, the long-term impact ...

    Authors: Brendan Curti, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, Meenu Kaur, Theresa L. Luna, Nancy Gregory, Michael A. Morse, Michael K. K. Wong and Janice P. Dutcher

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:102

    Published on:

  6. Content type: Research article

    Programmed cell death ligand-1 (PD-L1) expression has been reported in up to 61% of high grade gliomas (HGG). The purpose of this study was to describe safety and efficacy of PD-1 inhibition in patients with r...

    Authors: Samantha N. Reiss, Prakirthi Yerram, Lisa Modelevsky and Christian Grommes

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:99

    Published on:

  7. Content type: Research article

    Immunotherapies, specifically those based on immune checkpoint inhibitors, have shown promising activity in multiple tumor types. Other than mifamurtide (MEPACT®) for osteosarcoma approved by European Medicine...

    Authors: Roman Groisberg, David S. Hong, Amini Behrang, Kenneth Hess, Filip Janku, Sarina Piha-Paul, Aung Naing, Siqing Fu, Robert Benjamin, Shreyaskumar Patel, Neeta Somaiah, Anthony Conley, Funda Meric-Bernstam and Vivek Subbiah

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:100

    Published on:

  8. Content type: Research article

    Hepatocellular carcinoma (HCC) is a major health problem worldwide with increasing incidence rates. As HCC traditionally occurs in chronically inflamed livers, this inflammation aids to drive oncogenesis and o...

    Authors: Zachary J. Brown, Bernd Heinrich, Seth M. Steinberg, Su Jong Yu and Tim F. Greten

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:93

    Published on:

  9. Content type: Research article

    Breast cancer remains a leading cause of cancer death worldwide. There is evidence that immunotherapy may play a role in the eradication of residual disease. Peptide vaccines for immunotherapy are capable of d...

    Authors: Patrick M. Dillon, Gina R. Petroni, Mark E. Smolkin, David R. Brenin, Kimberly A. Chianese-Bullock, Kelly T. Smith, Walter C. Olson, Ibrahim S. Fanous, Carmel J. Nail, Christiana M. Brenin, Emily H. Hall and Craig L. Slingluff Jr

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:92

    Published on:

  10. Content type: Research article

    Checkpoint blockade with ipilimumab provides long-term survival to a significant proportion of patients with metastatic melanoma. New approaches to increase survival and to predict which patients will benefit ...

    Authors: Rahima Jamal, Réjean Lapointe, Eftihia Cocolakis, Paméla Thébault, Shirin Kazemi, Jennifer E. Friedmann, Jeanne Dionne, Jean-François Cailhier, Karl Bélanger, Jean-Pierre Ayoub, Huy Le, Caroline Lambert, Jida El-Hajjar, Léon C. van Kempen, Alan Spatz and Wilson H. Miller Jr

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:83

    Published on:

  11. Content type: Research Article

    Brain metastases are common in patients with metastatic melanoma. With increasing numbers of melanoma patients on anti-PD-1 therapy, we sought to evaluate the safety and initial response of brain metastases tr...

    Authors: Erik S. Anderson, Michael A. Postow, Jedd D. Wolchok, Robert J. Young, Åse Ballangrud, Timothy A. Chan, Yoshiya Yamada and Kathryn Beal

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:76

    Published on:

  12. Content type: Research article

    Durable remissions are observed in a fraction of metastatic melanoma patients treated with high-dose interleukin-2 (HD IL-2). Early studies reported overall (OR) and complete response (CR) rates of 16% and 8% ...

    Authors: Diwakar Davar, Fei Ding, Melissa Saul, Cindy Sander, Ahmad A. Tarhini, John M. Kirkwood and Hussein A. Tawbi

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:74

    Published on:

  13. Content type: Research article

    Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate (DRR; a continuous response [comple...

    Authors: Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov and Merrick Ross

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:72

    Published on:

  14. Content type: Research article

    Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival in co...

    Authors: Caroline Tosch, Bérangère Bastien, Luc Barraud, Benoit Grellier, Virginie Nourtier, Murielle Gantzer, Jean Marc Limacher, Eric Quemeneur, Kaïdre Bendjama and Xavier Préville

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:70

    Published on:

  15. Content type: Research article

    Adoptive natural killer (NK) cell transfer is being increasingly used as cancer treatment. However, clinical responses have so far been limited to patients with hematological malignancies. A potential limiting...

    Authors: Veronika Kremer, Marteen A. Ligtenberg, Rosa Zendehdel, Christina Seitz, Annet Duivenvoorden, Erik Wennerberg, Eugenia Colón, Ann-Helén Scherman-Plogell and Andreas Lundqvist

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:73

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2017 5:88

  16. Content type: Research article

    Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study assessed intravenous (IV) delivery of enadenotucirev in...

    Authors: Rocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, Ignacio Osman-Garcia, Luis Paz-Ares, Juan M. Bozada, Valentina Boni, Christine Blanc, Len Seymour, John Beadle, Simon Alvis, Brian Champion, Emiliano Calvo and Kerry Fisher

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:71

    Published on:

  17. Content type: Research article

    Accumulating pre-clinical data indicate that the efficient induction of antigen-specific cytotoxic CD8+ T cells characterizing viral infections is caused by cross-priming where initially infected DCs produce a...

    Authors: Anna Laurell, Maria Lönnemark, Einar Brekkan, Anders Magnusson, Anna Tolf, Anna Carin Wallgren, Bengt Andersson, Lars Adamson, Rolf Kiessling and Alex Karlsson-Parra

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:52

    Published on:

  18. Content type: Research article

    Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pe...

    Authors: Tomoko Freshwater, Anna Kondic, Malidi Ahamadi, Claire H. Li, Rik de Greef, Dinesh de Alwis and Julie A. Stone

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:43

    Published on:

  19. Content type: Research article

    Exercise immunology has become a growing field in the past 20 years, with an emphasis on understanding how different forms of exercise affect immune function. Mechanistic studies are beginning to shed light on...

    Authors: Michael P. Gustafson, Ara Celi DiCostanzo, Courtney M. Wheatley, Chul-Ho Kim, Svetlana Bornschlegl, Dennis A. Gastineau, Bruce D. Johnson and Allan B. Dietz

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:30

    Published on:

  20. Content type: Research article

    Tumor immune cell infiltrates are essential in hindering cancer progression and may complement the TNM classification. CD8+ and CD163+ cells have prognostic impact in breast cancer but their spatial heterogene...

    Authors: Sotirios P. Fortis, Michael Sofopoulos, Nectaria N. Sotiriadou, Christoforos Haritos, Christoforos K. Vaxevanis, Eleftheria A. Anastasopoulou, Nicole Janssen, Niki Arnogiannaki, Alexandros Ardavanis, Graham Pawelec, Sonia A. Perez and Constantin N. Baxevanis

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:39

    Published on:

    The Erratum to this article has been published in Journal for ImmunoTherapy of Cancer 2017 5:48

Previous Page Page 1 of 4 Next Page

2016 Journal Metrics

  • Speed
    27 days from submission to first decision
    11 days from acceptance to publication

    Usage 
    358,247 downloads
    1157.0 Usage Factor

    Social Media Impact
    114 mentions

Advertisement